Benzodiazepine Initiation Effect on Mortality Among Medicare Beneficiaries Post Acute Ischemic Stroke
Madhav Sankaranarayanan,Maria Andrea Donahue,Shuo Sun,Julianne D Brooks,Lee H. Schwamm,Joseph P Newhouse,John Hsu,Deborah Blacker,Sebastien Haneuse,Lidia M.V.R. Moura
DOI: https://doi.org/10.1101/2024.08.18.24312199
2024-08-20
Abstract:Despite guideline warnings against benzodiazepine (BZD) use in older acute ischemic stroke (AIS) survivors due to severe adverse effects, they are still being prescribed for agitation, insomnia, and anxiety. We examined the impact of receiving BZDs within 30 days post-discharge on survival among Medicare beneficiaries after an AIS.
We analyzed a selected sample of eligible Traditional Medicare beneficiaries enrolled for at least 12 months before admission using the Medicare Provider Analysis and Review dataset. We excluded those prescribed a BZD within 90 days before hospitalization, passed away during their hospital stay, left against medical advice, or were discharged to institutional post-acute care. Our primary exposure was BZD initiation within 30 days post-discharge, and its primary outcome on 90-day mortality risk differences (RDs) from discharge using trial emulation methods (i.e., cloning, weighting, censoring, and inverse-probability-of-censoring weighting) to address confounding.
Of 47,421 beneficiaries, 826 (1.74%) initiated BZD within 30 days post-discharge or before readmission, whichever occurred first, and 6,392 (13.48%) had a mortality event within 90 days. The median age was 79 (inter-quartile range 12), with a demographic composition of 55.3% female, 82.9% White, 10.1% Black, 1.7% Hispanic, 2.2% Asian, and 0.4% American Native. After standardization (based on age, sex, race/ethnicity, length of stay, and baseline dementia), the 90-day mortality risk revealed an RD of 26 events per 1,000 (95% CI: 22, 33). Subgroup analyses revealed higher RDs in older age groups, particularly those aged 86 or older, with an RD of 84 events per 1,000 (95% CI: 73, 106). Patients with baseline dementia had an RD of 87 events per 1,000 (95% CI: 63, 112), compared to 18 events per 1,000 (95% CI: 13, 21) for those without.
Initiating BZDs within 30 days post-AIS discharge significantly increased the 90-day mortality risk, especially in older adults 76 years and older and those with baseline dementia, highlighting their vulnerability to BZD adverse effects.